VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

AACR 2021 | CHRONOS-3: copanlisib plus rituximab for relapsed iNHL

Matthew Matasar, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, shares an update on the randomized Phase III CHRONOS-3 trial (NCT02367040) of copanlisib plus rituximab versus rituximab and placebo in patients with relapsed indolent non-Hodgkin lymphoma (iNHL). At a median follow-up of 19.2 months, copanlisib plus rituximab demonstrated superior efficacy compared to placebo plus rituximab in patients with relapsed iNHL, with a median progression-free survival (PFS) of 21.5 months versus 13.8 months. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Matthew Matasar, MD, has received support and honoraria from Bayer and Roche.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter